Advertisement
Advertisement
U.S. Markets open in 4 hrs 56 mins
Advertisement
Advertisement
Advertisement
Advertisement

Q BioMed Inc. (QBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
0.0165-0.0005 (-2.94%)
At close: 01:20PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0170
Open0.0179
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0163 - 0.0179
52 Week Range0.0120 - 0.6600
Volume177,704
Avg. Volume1,273,658
Market Cap471,876
Beta (5Y Monthly)2.48
PE Ratio (TTM)N/A
EPS (TTM)-0.4740
Earnings DateJul 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.

    Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce that it has converted its long-term royalty agreement into an equity stake in Mannin Research Inc. (MRI), a private Canadian controlled biotechnology company, based in Toronto, Ontario, Canada. The conversion results in two key outcomes: QBIO receives a 15% equity stake in the form of common shares in MRI at a current valuation of MRI at CAD$30 million, and a royalty payment of $20 mil

  • PR Newswire

    Q BIOMED PROVIDES SHAREHOLDER UPDATE

    Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotechnology acceleration development company, is pleased to provide an update to its shareholders.

  • PR Newswire

    Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER

    Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce receipt of a European Certificate of Grant for GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) licensed from the Washington University in St. Louis. Determining the severity of glaucoma using this biomarker will aid in treatment decisions for patients diagnosed with, and being treated for, glauc

Advertisement
Advertisement